Rifabutin is under clinical development by Bioversys and currently in Phase I for Bacterial Infections. According to GlobalData, Phase I drugs for Bacterial Infections have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rifabutin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rifabutin overview
Rifabutin is under development for the treatment of Carbapenem Resistant Acinetobacter baumannii (CRAB) ventilator associated bacterial pneumonia, bacterial infections, hospital acquired bacterial pneumonia and bloodstream infections. It is administered by intravenous route.
Bioversys overview
Bioversys is a biotechnology company that researches and develops small molecules which turn off drug resistance against existing antibiotics. The company product pipeline includes BV100 novel MoA, BV200 novel anti-virulence MoA, BVL-GSK098 novel potentiator MoA, BV300 – novel class. Its services includes Research and Development and Clinical Trials. It develops a pipeline product for the treatment of nosocomial infection. Bioversys addresses the medical need for new treatments against life-threatening bacterial infections and for the resistance of bacterial strains against existing antibiotics. The company also conducts research on nosocomial infections and tuberculosis. Bioversys is headquartered in Basel, Basel-Stadt, Switzerland.
For a complete picture of Rifabutin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
